OCTP, the pharmaceutical company developing prescription cannabinoid medicines, is formally expanding its research and development strategy into oncology having identified a potential “first in class” immunotherapy agent for the treatment of solid tumours. Initial data implies substantive potential for the development of a cannabinoid-based medicine that could be taken at home, as a tablet This 

​ OCTP, the pharmaceutical company developing prescription cannabinoid medicines, is formally expanding its research and development strategy into oncology having identified a potential “first in class” immunotherapy agent for the treatment of solid tumours. Initial data implies substantive potential for the development of a cannabinoid-based medicine that could be taken at home, as a tablet This […] 

​Read More 

Cannabis Law Report